Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Sebetralstat [inn]
2. Kvd900
3. Sebetralstat [usan]
4. O5zd2tu2b7
5. Kvd-900
6. 1933514-13-6
7. Unii-o5zd2tu2b7
8. Schembl17785421
9. Bdbm408717
10. Glxc-25706
11. Ex-a6252
12. Us10364238, Example 41
13. Who 11529
14. Hy-132830
15. Cs-0204137
16. 1h-pyrazole-4-carboxamide, N-((3-fluoro-4-methoxy-2-pyridinyl)methyl)-3-(methoxymethyl)-1-((4-((2-oxo-1(2h)-pyridinyl)methyl)phenyl)methyl)-
17. 1h-pyrazole-4-carboxamide, N-[(3-fluoro-4-methoxy-2-pyridinyl)methyl]-3-methoxymethyl)-1-[[4-[(2-oxo-1(2h)-pyridinyl)methyl]phenyl]methyl]-
18. N-((3-fluoro-4-methoxy-2-pyridinyl)methyl)-3-(methoxymethyl)-1-((4-((2-oxo-1(2h)-pyridinyl)methyl)phenyl)methyl)-1h-pyrazole-4-carboxamide
19. N-((3-fluoro-4-methoxypyridin-2-yl) Methyl)-3-(methoxymethyl)-1-((4-((2-oxo-1,2-dihydropyridin-1-yl) Methyl)phenyl)methyl)-1h-pyrazole-4-carboxamide
20. N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
21. N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1(2h)-yl)methyl]phenyl}methyl)-1h-pyrazol-4-carboxamide
| Molecular Weight | 491.5 g/mol |
|---|---|
| Molecular Formula | C26H26FN5O4 |
| XLogP3 | 1.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 10 |
| Exact Mass | 491.19688249 g/mol |
| Monoisotopic Mass | 491.19688249 g/mol |
| Topological Polar Surface Area | 98.6 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 803 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Under the licensing agreement, Kaken will holds the rights of KVD900 (sebetralstat) in Japan. It is being evaluated for the treatment of hereditary angioedema.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Kaken Pharmaceuticals
Deal Size: $22.0 million Upfront Cash: $11.0 million
Deal Type: Licensing Agreement April 08, 2025
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Kaken Pharmaceuticals
Deal Size : $22.0 million
Deal Type : Licensing Agreement
KalVista Licenses Sebetralstat to Kaken for HAE Market in Japan
Details : Under the licensing agreement, Kaken will holds the rights of KVD900 (sebetralstat) in Japan. It is being evaluated for the treatment of hereditary angioedema.
Product Name : KVD900
Product Type : Other Small Molecule
Upfront Cash : $11.0 million
April 08, 2025
Details:
KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 2 to 11 years.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 25, 2025
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
KalVista Completes KONFIDENT-KID Pediatric HAE Trial Enrollment Early
Details : KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 2 to 11 years.
Product Name : KVD900
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 25, 2025
Details:
KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 2 to 11 years.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 21, 2025
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
KalVista Announces Orphan Drug Designation for Sebetralstat in Hereditary Angioedema
Details : KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 2 to 11 years.
Product Name : KVD900
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2025
Details:
KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 03, 2024
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
KalVista Pharmaceuticals Awarded UK PIM Designation for Sebetralstat
Details : KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema.
Product Name : KVD900
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2024
Details:
KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 2 to 11 years.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 30, 2024
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
KalVista Submits MAAs For Sebetralstat For Hereditary Angioedema
Details : KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 2 to 11 years.
Product Name : KVD900
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2024
Details:
KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 2 to 11 years.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 27, 2024
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
KalVista Initiates KONFIDENT-KID Trial for Sebetralstat in Children with Angioedema
Details : KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 2 to 11 years.
Product Name : KVD900
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 27, 2024
Details:
KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 12 years & older.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 18, 2024
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
KalVista Submits NDA for Sebetralstat for Hereditary Angioedema
Details : KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 12 years & older.
Product Name : KVD900
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 18, 2024
Details:
KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 2 to 11 years.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 09, 2024
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
KalVista Secures FDA Approval of NDA for Sebetralstat in Hereditary Angioedema
Details : KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 2 to 11 years.
Product Name : KVD900
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 09, 2024
Details:
The proceeds will support clinical trials and product development of KVD900 (sebetralstat), a plasma kallikrein inhibitor for hereditary angioedema.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Jefferies
Deal Size: $160.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 15, 2024
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Jefferies
Deal Size : $160.1 million
Deal Type : Public Offering
KalVista Pharmaceuticals Prices $160.1 Million Public Offering
Details : The proceeds will support clinical trials and product development of KVD900 (sebetralstat), a plasma kallikrein inhibitor for hereditary angioedema.
Product Name : KVD900
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 15, 2024
Details:
The net proceeds will be used for the clinical development of KVD900 (sebetraslat), which is an oral plasma kallikrein inhibitor used for the treatment of hereditary angioedema.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Jefferies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering February 14, 2024
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Jefferies
Deal Size : Undisclosed
Deal Type : Public Offering
KalVista Pharmaceuticals Proposes Public Offering of Common Stock and Pre-Funded Warrants
Details : The net proceeds will be used for the clinical development of KVD900 (sebetraslat), which is an oral plasma kallikrein inhibitor used for the treatment of hereditary angioedema.
Product Name : KVD900
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 14, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
10
PharmaCompass offers a list of Sebetralstat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sebetralstat manufacturer or Sebetralstat supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sebetralstat manufacturer or Sebetralstat supplier.
PharmaCompass also assists you with knowing the Sebetralstat API Price utilized in the formulation of products. Sebetralstat API Price is not always fixed or binding as the Sebetralstat Price is obtained through a variety of data sources. The Sebetralstat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Sebetralstat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sebetralstat, including repackagers and relabelers. The FDA regulates Sebetralstat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sebetralstat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Sebetralstat supplier is an individual or a company that provides Sebetralstat active pharmaceutical ingredient (API) or Sebetralstat finished formulations upon request. The Sebetralstat suppliers may include Sebetralstat API manufacturers, exporters, distributors and traders.
Sebetralstat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sebetralstat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sebetralstat GMP manufacturer or Sebetralstat GMP API supplier for your needs.
A Sebetralstat CoA (Certificate of Analysis) is a formal document that attests to Sebetralstat's compliance with Sebetralstat specifications and serves as a tool for batch-level quality control.
Sebetralstat CoA mostly includes findings from lab analyses of a specific batch. For each Sebetralstat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sebetralstat may be tested according to a variety of international standards, such as European Pharmacopoeia (Sebetralstat EP), Sebetralstat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sebetralstat USP).
